[Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2006].
The antibacterial activity of meropenem (MEPM) and other parenteral antibiotics against clinical isolates of 876 strains of Gram-positive bacteria, 1764 strains of Gram-negative bacteria, and 198 strains of anaerobic bacteria obtained from 30 medical institutions during 2006 was measured. The results were as follows; 1. MEPM was more active than the other carbapenem antibiotics tested against Gram-negative bacteria, especially against enterobacteriaceae and Haemophilus influenzae. MEPM was also active against most of the species tested in Gram-positive and anaerobic bacteria, except for multi-drug resistant strains including methicillin-resistant Staphylococcus aureus. 2. As for Pseudomonas aeruginosa, all of the MEPM-resistant strains were resistant to imipenem (IPM). MEPM showed low cross-resistant rate both againt IPM-resistant P. aeruginosa (41.8%) and ciprofloxacin-resistant P. aeruginosa (33.3%). 3. The proportion of extended-spectrum beta-lactamase (ESBL) strains was 4.3% (6 strains) in Escherichia coli, 1.1% (1 strain) in Citrobacter freundii, 21.7% (5 strains) in Citrobacter koseri, 3.1% (4 strains) in Klebsiella pneumoniae, 3.3% (3 strains) in Enterobacter cloacae, 0.8% (1 strain) in Serratia marcescens, and 4.9% (2 strains) in Providencia spp. The proportion of metallo-beta-lactamase strains was 3.1% (10 strains) in P. aeruginosa. 4. Of all species tested, there were no species, which MIC90 of MEPM was more than 4-fold higher than those in our previous study. Therefore, there is almost no significant decrease in susceptibility of clinical isolates to meropenem. In conclusion, the results from this surveillance study suggest that MEPM retains its potent and broad antibacterial activity and therefore is a clinically useful carbapenem at present, 11 years after available for commercial use.
Yamaguchi
Keizo
K
Department of Microbiology and Infectious Diseases, Toho University School of Medicine.
Ishii
Yoshikazu
Y
Iwata
Morihiro
M
Watanabe
Naoki
N
Uehara
Nobuyuki
N
Yasujima
Minoru
M
Kasai
Takeshi
T
Suwabe
Akira
A
Yamahata
Kumiko
K
Kaku
Mitsuo
M
Kanemitsu
Keiji
K
Imafuku
Yuji
Y
Nishiyama
Kyouko
K
Murakami
Masami
M
Yomoda
Sachie
S
Taniguchi
Nobuyuki
N
Yamada
Toshiyuki
T
Nomura
Fumio
F
Watanabe
Masaharu
M
Kanno
Harushige
H
Aihara
Masanori
M
Maesaki
Shigefumi
S
Hashikita
Giichi
G
Kondo
Shigemi
S
Misawa
Shigeki
S
Horiuchi
Hajime
H
Tazawa
Yoko
Y
Nakashima
Hideki
H
Takemura
Hiromu
H
Okada
Masahiko
M
Yamazaki
Fusako
F
Horii
Toshinobu
T
Maekawa
Masato
M
Baba
Hisashi
H
Ishigo
Shiomi
S
Fujita
Naohisa
N
Komori
Toshiaki
T
Ichiyama
Satoshi
S
Iinuma
Yoshitsugu
Y
Maeda
Shigetaka
S
Yamanaka
Kiyoharu
K
Murata
Yoko
Y
Matsuo
Shuji
S
Kohno
Hisashi
H
Kinoshita
Shohiro
S
Fujita
Jun
J
Negayama
Kiyoshi
K
Murase
Mitsuharu
M
Miyamoto
Hitoshi
H
Kusano
Nobuchika
N
Mihara
Eiichirou
E
Itaha
Hideyuki
H
Ono
Junko
J
Yoshimura
Hisae
H
Yanagihara
Katsunori
K
Matsuda
Junichi
J
Saikawa
Tetsunori
T
Hiramatsu
Kazufumi
K
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D024881:Drug Resistance, Bacterial; D006090:Gram-Negative Bacteria / Q000187:drug effects* / Q000201:enzymology / Q000302:isolation & purification; D016905:Gram-Negative Bacterial Infections / Q000382:microbiology; D006094:Gram-Positive Bacteria / Q000187:drug effects* / Q000201:enzymology / Q000302:isolation & purification; D016908:Gram-Positive Bacterial Infections / Q000382:microbiology; D006801:Humans; D007275:Injections, Intravenous; D007564:Japan; D000077731:Meropenem; D013845:Thienamycins / Q000494:pharmacology*; D013997:Time Factors; D001618:beta-Lactamases / Q000096:biosynthesis
D000900:Anti-Bacterial Agents; D013845:Thienamycins; D001618:beta-Lactamases; D000077731:Meropenem